CAREERS AT BIOMARIN
Our focus on rare disease gives us the rare opportunity to truly impact lives.
Learn More about careers with BioMarin ⌃
OUR MOTIVATION
We are inspired and driven everyday by stories like Sheri’s.
Learn More about Sheri ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies
OUR PIPELINE
We take on the biggest challenges in rare disease.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it
-
September 6, 2021U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
-
August 27, 2021European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
-
August 25, 2021BioMarin to Participate in Three Upcoming Virtual Investor Conferences
-
July 28, 2021BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates
-
July 21, 2021BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstrating Continued, Durable Clinical Benefit
-
July 19, 2021BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress
-
July 15, 2021European Medicines Agency Validates BioMarin’s Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
-
July 14, 2021BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET